S
Santiago Ferrer
Researcher at GlaxoSmithKline
Publications - 54
Citations - 3222
Santiago Ferrer is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Plasmodium falciparum & Plasmodium berghei. The author has an hindex of 25, co-authored 53 publications receiving 2803 citations. Previous affiliations of Santiago Ferrer include Niigata University & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Chemical genetics of Plasmodium falciparum.
W. Armand Guiguemde,Anang A. Shelat,David Bouck,Sandra Duffy,Gregory J. Crowther,Paul H. Davis,David C. Smithson,Michele Connelly,Julie Clark,Fangyi Zhu,María Belén Jiménez-Díaz,María Santos Martínez,Emily Wilson,Abhai K. Tripathi,Jiri Gut,Elizabeth R. Sharlow,Ian Bathurst,Farah El Mazouni,Joseph W. Fowble,Isaac P. Forquer,Paula L. McGinley,Steve Castro,Iñigo Angulo-Barturen,Santiago Ferrer,Philip J. Rosenthal,Joseph L. DeRisi,David J. Sullivan,John S. Lazo,David S. Roos,Michael K. Riscoe,Margaret A. Phillips,Pradipsinh K. Rathod,Wesley C. Van Voorhis,Vicky M. Avery,R. Kiplin Guy +34 more
TL;DR: A phenotypic forward chemical genetic approach to discover new antimalarial chemotypes and structures and biological activity of the entire library are disclosed, many of which showed potent in vitro activity against drug-resistant P. falciparum strains.
Journal ArticleDOI
Quinolone-3-Diarylethers: A New Class of Antimalarial Drug
Aaron Nilsen,Alexis N. LaCrue,Karen L. White,Isaac P. Forquer,R. Matthew Cross,Jutta Marfurt,Michael W. Mather,Michael J. Delves,David M. Shackleford,Fabián E. Sáenz,Joanne M. Morrisey,Jessica Anne Steuten,Tina Mutka,Yuexin Li,Grennady Wirjanata,Eileen Ryan,Sandra Duffy,Jane X. Kelly,Boni F. Sebayang,Anne-Marie Zeeman,Rintis Noviyanti,Robert E. Sinden,Clemens H. M. Kocken,Ric N. Price,Ric N. Price,Vicky M. Avery,Iñigo Angulo-Barturen,María Belén Jiménez-Díaz,Santiago Ferrer,Esperanza Herreros,Laura M. Sanz,Francisco-Javier Gamo,Ian Bathurst,Jeremy N. Burrows,Peter Siegl,R. Kiplin Guy,Rolf W. Winter,Akhil B. Vaidya,Susan A. Charman,Dennis E. Kyle,Roman Manetsch,Michael K. Riscoe +41 more
TL;DR: ELQ-300, a 4(1H)-quinolone-3-diarylether, which targets the liver and blood stages, including the forms that are crucial to disease transmission (gametocytes, zygotes, and ookinetes), has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.
Journal ArticleDOI
Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential
Jose M. Coteron,Maria L. Marco,Jorge Esquivias,Xiaoyi Deng,Karen L. White,John H. White,Maria Koltun,Farah El Mazouni,Sreekanth Kokkonda,Kasiram Katneni,Ravi K. Bhamidipati,David M. Shackleford,Iñigo Angulo-Barturen,Santiago Ferrer,María Belén Jiménez-Díaz,Francisco-Javier Gamo,Elizabeth J. Goldsmith,William N. Charman,Ian Bathurst,David M. Floyd,David Matthews,Jeremy N. Burrows,Pradipsinh K. Rathod,Susan A. Charman,Margaret A. Phillips +24 more
TL;DR: These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound toward clinical candidate status.
Journal ArticleDOI
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
María Belén Jiménez-Díaz,Daniel H. Ebert,Yandira G. Salinas,Anupam Pradhan,Adele M. Lehane,Marie-Eve Myrand-Lapierre,Kathleen O’Loughlin,David M. Shackleford,Mariana Justino de Almeida,Angela K. Carrillo,Julie Clark,Adelaide S. M. Dennis,Jonathon Diep,Xiaoyan Deng,Sandra Duffy,Aaron N. Endsley,Greg Fedewa,W. Armand Guiguemde,María G. Gómez,Gloria Holbrook,Jeremy A. Horst,Charles C. Kim,Jian Liu,Marcus C. S. Lee,Amy Matheny,María Santos Martínez,Gregory M. Miller,Ane Rodríguez-Alejandre,Laura M. Sanz,Martina Sigal,Natalie J. Spillman,Philip D. Stein,Zheng Wang,Fangyi Zhu,David Waterson,Spencer Knapp,Anang A. Shelat,Vicky M. Avery,David A. Fidock,Francisco-Javier Gamo,Susan A. Charman,Jon C. Mirsalis,Hongshen Ma,Santiago Ferrer,Kiaran Kirk,Iñigo Angulo-Barturen,Dennis E. Kyle,Joseph L. DeRisi,David M. Floyd,R. Kiplin Guy +49 more
TL;DR: The results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication and suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.
Journal ArticleDOI
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
Tanya Paquet,Claire Le Manach,Diego Gonzàlez Cabrera,Yassir Younis,Philipp P. Henrich,Tara S. Abraham,Tara S. Abraham,Marcus C. S. Lee,Marcus C. S. Lee,Rajshekhar Basak,Rajshekhar Basak,Sonja Ghidelli-Disse,Maria Jose Lafuente-Monasterio,Marcus Bantscheff,Andrea Ruecker,Andrew M. Blagborough,Sara E. Zakutansky,Anne-Marie Zeeman,Karen L. White,David M. Shackleford,Janne Mannila,Julia Morizzi,Christian Scheurer,Christian Scheurer,Iñigo Angulo-Barturen,María Santos Martínez,Santiago Ferrer,Laura M. Sanz,Francisco-Javier Gamo,Janette Reader,Mariette Botha,Koen J. Dechering,Robert W. Sauerwein,Anchalee Tungtaeng,Pattaraporn Vanachayangkul,Chek Shik Lim,Jeremy N. Burrows,Michael J Witty,Michael J Witty,Kennan C. Marsh,Christophe Bodenreider,Rosemary Rochford,Suresh Solapure,María Belén Jiménez-Díaz,Sergio Wittlin,Sergio Wittlin,Susan A. Charman,Cristina Donini,Brice Campo,Lyn-Marie Birkholtz,Kirsten K. Hanson,Gerard Drewes,Clemens H. M. Kocken,Michael J. Delves,Didier Leroy,David A. Fidock,David Waterson,David Waterson,Leslie J. Street,Kelly Chibale,Kelly Chibale +60 more
TL;DR: The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.